Comparison of the Digene HPV Genotyping LQ Test and the PANArray HPV Genotyping Chip for Detection of High-Risk or Probable High-Risk Human Papillomavirus Genotypes

Kyung Sun Park, M.D., Ji-Youn Kim, M.T., Chang-Seok Ki, M.D., and Nam Yong Lee, M.D.
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Background: We evaluated the performance of two different array-based techniques, a bead-based multiplex genotyping method (LQ; digene HPV Genotyping LQ Test, QIAGEN, Germany) and a DNA chip-based method using peptide nucleic acid probes (PANArray; PANArray HPV Genotyping Chip, Panagene, Korea), for detection of human papillomavirus (HPV) and genotyping of high-risk (HR) or probable high-risk (PHR) HPVs in healthy patients who visited a health-promotion center.

Methods: We obtained 508 unselected, consecutive cervicovaginal swab specimens. All specimens were examined by using the PANArray and LQ tests. All HPV-positive samples were then analyzed by multiplex PCR and direct sequencing.

Results: The LQ test detected 47 HPV-positive cases (9.3%) with HR or PHR genotypes and the PANArray test identified 36 cases (7.1%). When the results of LQ and PANArray were compared by using comprehensive genotyping (integrated interpretation of the results of LQ, PANArray, multiplex PCR, and direct sequencing) for the detection of HR or PHR genotypes, the kappa values were 0.44 and 0.30 for LQ and PANArray, respectively. In comparison to comprehensive genotyping, the LQ test yielded 53 (60.0%) concordant and 12 (13.5%) compatible results, and the PANArray yielded 36 (40.4%) concordant and three (3.4%) compatible results.

Conclusions: The results of the LQ test had higher concordance and/or greater compatibility with those of comprehensive genotyping for the detection of HR or PHR genotypes than those of the PANArray test.

Key Words: Human papillomavirus, DNA test, Comparison, Genotyping

INTRODUCTION

More than 100 human papillomavirus (HPV) genotypes have been reported [1]. Previous studies on the epidemiologic classification of HPV associated with cervical cancer found that HPV can be grouped into high-risk (HR), probable high-risk (PHR), and low-risk (LR) HPV genotypic groups according to their carcinogenic potential [2]. Recently, the International Agency for Research on Cancer (IARC) defined the HPV16 type, which is known to cause cancer at several sites, as the most potent carcinogenic HPV type [3]. HPV types 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 were classified as Group 1, which indicates that there is sufficient evidence that these strains cause cervical cancer.

Numerous commercially-available or laboratory-developed HPV typing methods have been introduced to date. These tests...
have been based on different methods, including DNA-RNA hybrid capture, real-time PCR-based assays, microarray-based assays, suspension array-based assays, and direct sequencing [4, 5]. Several array-based techniques have also been developed, which consist of type-specific oligonucleotide or PCR amplicon probes immobilized on solid surfaces, such as glass, membranes, or liquid beads. These techniques are useful for HPV genotyping, because they allow for rapid and simultaneous identification of various viruses or of the same virus with different genotypes in a single assay [6]. However, array-based techniques are difficult to standardize owing to their large number of probes, and exhibit low reproducibility because of non-specific hybridization reactions [7].

Since their introduction, several studies comparing the performance of these array-based techniques with that of other more well-established HPV detection methods have been conducted [8-10]. However, few studies have compared the different multiplex array-based techniques using clinical samples [11].

Among the commercially available array-based methods, the *Digene* HPV Genotyping LQ Test (LQ; QIAGEN, Hilden, Germany) uses multiplex, liquid bead-based xMAP suspension array technology to identify 18 HR HPV types [9]. The PANArray HPV Genotyping Chip (PANArray; PANAGENE, Daejeon, Korea) is a peptide nucleic acid (PNA)-based array and uses the DNA chip technology. This technique uses a microarray platform with PNA probes, which have better chemical and enzymatic stability than DNA oligonucleotide probes [12].

The present study aimed to evaluate the performance of two different array-based techniques—the bead-based multiplex genotyping method (LQ) and the DNA chip technology using PNA probes (PANArray)—for HPV detection and genotyping of HR or PHR HPV in Korean women seeking routine screening for cervical cancer.

**METHODS**

1. Clinical specimens
   This was a prospective study conducted in a routine diagnostic laboratory setting at the Samsung Medical Center, Seoul, Korea; the study protocol was approved by the Institutional Review Board (IRB) of Samsung Medical Center (IRB No. 2011-02-045). Five hundred and eight, unselected, consecutive cervical-vaginal swab specimens were obtained from women visiting a health-promotion center by using a cytobrush.

   The mean age of the 508 patients was 52 yr (range, 27 to 82 yr). The cytologic diagnoses were: 495 (97.4%) normal, 5 (1.0%) atypical squamous cells of undetermined significance (ASCUS), and 8 (1.6%) low-grade squamous intraepithelial lesions (LSIL). There were no patients with high-grade squamous intraepithelial lesions (HSIL).

   All specimens were tested for HPV, as well as carrying out HPV genotyping, using both PANArray and LQ tests. The HPV-positive samples thus identified were additionally analyzed by multiplex PCR and direct sequencing (Fig. 1).

2. *Digene* HPV genotyping LQ test
   DNA was extracted by using a QiAmp minElute Virus Spin Kit (Qiagen) and a 100 μL was eluted from 200 μL of the sample. The LQ test utilizes probes for 18 HR or PHR HPV genotypes (Table 1), as identified in previous reports on the classification of HPV types associated with cervical cancer [2, 3]. The probes for HPV detection were immobilized on color-coded microbeads and a single color per HPV genotype was detected. The LQ test was performed by using the Luminex 100 IS system (Luminex Corporation, Austin, TX, USA) according to the manufacturer’s instructions. A positivity threshold of 100 median fluorescence intensity (MFI) was applied.

3. PANArray HPV genotyping chip
   DNA was extracted according to the manufacturer’s instructions by using a heating method, in which 1 mL of a liquid-based preparation of a cervical specimen was transferred to phosphate-buffered saline (PBS). This mixture was centrifuged, and then 20 μL of DNA extraction buffer was added. The sample was subsequently heated at 55°C for 1 hr and at 110°C for 28 min. After further centrifugation at 12,000 rpm for 5 min, 90 μL of the supernatant was used as the source of DNA for PCR analysis. The PANArray can detect 20 HR or PHR HPV genotypes and 12 LR genotypes (Table 1).

4. Multiplex PCR and direct sequencing
   Direct sequencing was performed as previously described by using the primers GP5+/6+ [13], MY09/11 [13], or PGMY09/11 [14] (Table 1). Multiplex PCR can detect 14 HR or PHR genotypes and 2 LR genotypes (Table 1) [15].

5. Comprehensive genotyping
   Comprehensive HPV genotyping was based primarily on the results of direct sequencing. In addition, two or more concordant results between LQ, PANArray, and multiplex PCR tests in the absence of a direct sequencing result were considered part of the comprehensive HPV genotyping (Fig. 1).
6. Statistical analysis

Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) and MedCalc software (MedCalc software, Mariakerke, Belgium). We calculated kappa inter-rater agreement values with 95% confidence intervals (CI) to compare the detection of HR or PHR HPV genotypes between the LQ and PANArray test results using the comprehensive genotyping results as the reference value. Kappa values are interpreted as follows: 0.0-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1 as almost perfect agreement.
RESULTS

Among the 508 specimens, the LQ test detected 47 (9.3%) HPV cases with HR or PHR genotypes, and the PANArray test identified 36 cases (7.1%) with HR or PHR genotypes and 33 cases (6.5%) with LR genotypes (Fig. 1). There were 89 HPV-positive specimens identified by LQ and/or PANArray testing, and these were analyzed further by multiplex PCR and direct sequencing. The detection rates of HR or PHR genotypes were 52.8% (47/89) by the LQ test, 40.4% (36/89) by the PANArray test, 20.2% (18/89) by multiplex PCR, and 24.7% (22/89) by direct sequencing. Thirty-six cases (40.4%) were determined to be HR or PHR genotypes using comprehensive genotyping based on integrated interpretation of the results of all 4 assays.

Because the LQ test can detect only 18 HR or PHR genotypes (Table 1), we assigned the results to 2 groups: HR or PHR and LR or HPV-negative to facilitate direct comparison of the results of LQ and PANArray, LQ and comprehensive genotyping, and PANArray and comprehensive genotyping. For all specimens, the results of the LQ and PANArray showed 90.6% agreement with a kappa value of 0.36 (95% CI, 0.22-0.51).

Table 2. Comparison of high-risk (HR) and probable high-risk (PHR) group genotyping findings using the digene HPV genotyping LQ test, the PANArray HPV genotyping chip, and comprehensive genotyping as reference values

| Assay       | Result by assay                  | Result by Comprehensive genotyping | Kappa (95% CI) |
|-------------|----------------------------------|-----------------------------------|----------------|
|            | HR/PHR (N = 36)                  | LR/NEG (N = 53)                   |                |
| LQ          | 29                               | 18                                | 0.44 (0.27 to 0.62) |
|            | NEG (N = 42)                     |                                   |                |
| PANArray    | 21†                             | 15                                | 0.30 (0.10 to 0.50) |
|            |                                  |                                   |                |

*If the case had at least one HR or PHR HPV genotype, it was considered HR- or PHR-positive.
†In one case, the genotype detected by the comprehensive genotyping was genotype 70, which could not be detected by the LQ assay; in two cases, the genotype detected by the comprehensive genotyping and PANArray was different. The results of comprehensive genotyping vs. PANArray were genotype 31 vs. genotype 18 and genotype 53 vs. genotype 68, respectively.

Abbreviations: HR, high-risk; PHR, probable high-risk; LR, low-risk; NEG, negative; CI, confidence interval.

DISCUSSION

In the present study, we compared the performance of 2 array-based techniques for HPV genotyping using clinical samples from visitors to a health promotion center. We used multiplex PCR and direct sequencing, in addition to comprehensive genotyping (integrated interpretation of the results of LQ, PANArray, multiplex PCR, and direct sequencing) as reference methods.

Recent studies have evaluated the performance of the digene HPV genotyping LQ test in comparison with those of other established HPV genotyping methods [8, 9, 16]. In these studies, the LQ test showed high concordance with the reference methods with respect to HR HPV detection, with kappa values of 0.884 between LQ and the reverse line blot assay [16], 0.923 between LQ and the Amplicor HPV test (Roche Molecular Diagnostics, Pleasanton, CA, USA) [9], and 0.94 between LQ and the Hybrid Capture 2 test (HC2; Qiagen, Gaithersburg, MD, USA) [8].

Studies evaluating DNA chip-based methods for detection of HR HPV genotypes also reported high concordance with the results of reference methods for HR HPV detection, with kappa values of 0.894 between LQ and the reverse line blot assay [16], 0.923 between LQ and the Amplicor HPV test (Roche Molecular Diagnostics, Pleasanton, CA, USA) [9], and 0.94 between LQ and the Hybrid Capture 2 test (HC2; Qiagen, Gaithersburg, MD, USA) [8].

The remaining 7 cases were determined by comprehensive analysis of the results of 4 assays (Table 3).
Table 3. Results of the comparison of LQ, PANArray, multiplex PCR, and direct sequencing with the comprehensive genotyping results used as the reference values

| Comprehensive genotyping | LQ | PANArray | Multiplex PCR | Direct sequencing |
|--------------------------|-----------------------------------|-----------------|-----------------|-----------------|
| Group (N)                | Result (N of typing) | Result (N of typing) | Result (N of typing) | Result (N of typing) |
| Genotype (N)             | N of CC/CP/DC | N of CC/CP/DC | N of CC/CP/DC | N of CC/CP/DC |
| HR/PHR (36)              | 16 (2) | 16 (2) | 16 (2) | 16 (2) |
| 11/16 (1)                | 11/16 (1) | 11/16 (1) | 11/16 (1) | 11/16 (1) |
| 18 (1)                   | 18 (1) | 18 (1) | 18 (1) | 18 (1) |
| 31 (2)                   | 31 (2) | 31 (2) | 31 (2) | 31 (2) |
| 33 (1)                   | 33 (1) | Other (1) | Other (1) | Other (1) |
| 35 (1)                   | 35 (1) | Other (1) | Other (1) | Other (1) |
| 39/51 (1)                | 39/51 (1) | 39/51 (1) | 39/51 (1) | 39/51 (1) |
| 39/52 (1)                | 39/52 (1) | 39/52 (1) | 39/52 (1) | 39/52 (1) |
| 39/81 (1)                | NEG (1) | 39/81 (1) | 39/81 (1) | 39/81 (1) |
| 45 (1)                   | 45 (1) | 45 (1) | 45 (1) | 45 (1) |
| 51 (3)                   | 51 (3), 51/56 (1) | 51 (1), NEG(2) | 51 (1), NEG(2) | 51 (1), NEG(2) |
| 52 (2)                   | 52 (2) | 52 (2) | 52 (2) | 52 (2) |
| 53 (3)                   | 53 (3), NEG (2) | 62 (1), 68 (1), other (1) | 62 (1), 68 (1), other (1) | 62 (1), 68 (1), other (1) |
| 53/56 (1)                | 56 (1) | 56 (1) | 56 (1) | 56 (1) |
| 53/62 (2)                | NEG (2) | 53 (1), 40 (1) | 53 (1), 40 (1) | 53 (1), 40 (1) |
| 56 (2)                   | 56 (2) | 56 (2) | 56 (2) | 56 (2) |
| 58 (3)                   | 58 (3) | 58 (3) | 58 (3) | 58 (3) |
| 66 (1)                   | 66 (1) | 66 (1) | 66 (1) | 66 (1) |
| 6/66 (1)                 | 66 (1) | 66 (1) | 66 (1) | 66 (1) |
| 62/66 (1)                | 62 (1) | 62 (1) | 62 (1) | 62 (1) |
| 68 (4)                   | 68 (4) | 68 (4) | 68 (4) | 68 (4) |
| 70 (1)                   | NEG (1) | 70 (1) | 70 (1) | 70 (1) |
| LR (7)                   | NEG (1) | NEG (1) | NEG (1) | NEG (1) |
| 54 (3)                   | NEG (3) | 54 (2), other (1) | 54 (2), other (1) | 54 (2), other (1) |
| 61 (1)                   | NEG (1) | 70 (1) | 70 (1) | 70 (1) |
| 62 (1)                   | NEG (1) | Other (1) | Other (1) | Other (1) |
| 72 (1)                   | NEG (1) | Other (1) | Other (1) | Other (1) |
| NEG* (46)                | None (46) | NEG (28), 16 (3), 16/45 (1), 16/58 (1), 18 (6), 33 (1), 45 (1), 58 (3), 66 (2) | 16/0/30 | NEG (46) |
| Total N of HR/PHR (36)   | 25/5/6 | 25/5/6 | 25/5/6 | 25/5/6 |
| Total N (89)             | 53/12/24 | 53/12/24 | 53/12/24 | 53/12/24 |

A concordant result indicates that both methods (between each assay and comprehensive genotyping) showed complete match of genotypes. A compatible result indicates that both methods demonstrated at least one genotype in common. If the assays could not distinguish or detect the specific genotypes by comprehensive genotyping, and therefore obtained negative results for HPV, these cases were regarded as compatible. A discordant result indicates that both methods (between each assay and comprehensive genotyping) showed no similarity between genotypes.

Abbreviations: HR, high-risk; PHR, probable high-risk; LR, low-risk; NEG, negative; CC, concordant; CP, compatible; DC, discordant.

*HPV-negative group by comprehensive genotyping included any disagreements among the tests (LQ, PANArray, Multiplex PCR and/or direct sequencing) as well as negative results for detection of HPV.
The results of the present study differ from those of prior studies for several reasons. We used a prospective, unselected study design and used clinical specimens from healthy visitors to a health promotion center, rather than specimens from visitors presented to a gynecology clinic for cervical cancer screening. Many prior studies comparing HPV genotyping assays used selective positive samples as determined by other assays such as HC2 or PCR [8, 16, 19] or clinical samples with abnormal cytology [17, 18]. Therefore, a relatively high proportion of samples with HSIL were included in these studies. However, when HPV genotyping assays are used for HR HPV detection and HPV genotyping in a routine diagnostic laboratory, HSIL specimens are not likely to be encountered.

According to the previous studies [20, 21], although the HPV DNA viral load does not correlate with histomorphological findings (normal; cervical intraepithelial neoplasia grades CIN1, CIN2, or CIN3; and cervical squamous cell carcinoma), statistically significant differences were present between all grades of CIN and the group lacking CIN [20]. In addition, the association of viral load with lesion grade may change depending on HPV genotype [21]. In the present study, the cytologic findings of nearly all enrolled cases were normal (97.4%), which implies that if these individuals had HPV, they might have a lower HPV DNA viral load than did patients included in the previous studies.

We observed several cases where HR HPV was detected by 2 or more tests among LQ, PANArray, and multiplex PCR, but not by direct sequencing, and vice versa. We surmise that the low HPV DNA viral load in our samples may have affected the results of these assays. The different assays may also differ in diagnostic sensitivity across HPV genotypes. Considering this potential limitation, we used comprehensive genotyping as the reference method. Therefore, the detection rate of HR or PHR genotypes using comprehensive genotyping was higher than that of direct sequencing (24.7% [22/87] vs. 40.4% [36/87]).

Direct sequencing results were given priority to determine the comprehensive HPV genotype, but we also considered concordant positive results from the other assays. Although direct sequencing is the gold standard for viral typing, it has limitations with regards to detecting multiple HPV genotypes [22]. Similar observations were made in the present study, where comprehensive genotyping detected 7 additional cases with multiple infections relative to those detected by direct sequencing. If subjects had multiple HPV genotypes, with each HPV genotype being present at a low DNA concentration, direct sequencing alone might not be sufficient for accurate detection.

The present study had some limitations. We could not compare a large number of HPV genotypes between assays because of the low number of HR HPV-positive specimens. In particular, the numbers of HPV 16- and HPV 18-positive samples were low, which are the most potent HPV types for inducing cervical cancer. Furthermore, to understand the reason behind the difference between the assay results, a comparative analysis of the detection limits for each HPV type should be conducted.

In conclusion, for the detection of HR or PHR genotypes, the results of the LQ assay had higher concordance or compatibility with those of comprehensive genotyping than those of PANArray assay.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**Acknowledgments**

This study was supported by Qiagen Korea. The sponsor had no involvement in the study design, data interpretation, and writing of the manuscript.

**REFERENCES**

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
2. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009;10:321-2.
4. Poljak M and Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-62.
5. Hwang Y and Lee M. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med 2012;32:201-5.
6. Loy A and Bodrossy L. Highly parallel microbial diagnostics using oligonucleotide microarrays. Clin Chim Acta 2006;363:106-19.
7. Clewley JP. A role for arrays in clinical virology: fact or fiction? J Clin Virol 2004;29:2-12.
8. Godínez JM, Tous S, Baixeras N, Moreno-Crespi J, Alejo M, Lejeune M, et al. Performance of the digene LQ, RH and PS HPV genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infect Agent Cancer 2011;6:23.
9. Geraets DT, Lenselink CH, Bekkers RL, van Doorn LJ, Quint WG, Melchers WJ. Universal human papillomavirus genotyping by the di-gene HPV Genotyping RH and LQ Tests. J Clin Virol 2011;50:276-80.
10. Zubach V, Smart G, Ratnam S, Severini A. Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types. J Clin Microbiol 2012;50:460-4.
11. Cho EJ, Do JH, Kim YS, Bae S, Ahn WS. Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods. J Med Microbiol 2011;60:162-71.
12. Choi JJ, Kim C, Park H. Peptide nucleic acid-based array for detecting and genotyping human papillomaviruses. J Clin Microbiol 2009;47:1785-90.
13. Husnjak K, Grce M, Magdić L, Pavelić K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods 2000;88:125-34.
14. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
15. Nishiwaki M, Yamamoto T, Tone S, Murai T, Ohkawara T, Matsunami T, et al. Genotyping of human papillomaviruses by a novel one-step typing method with multiplex PCR and clinical applications. J Clin Microbiol 2008;46:1161-8.
16. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, van Alewijk DC, Meijer CJ, et al. High-throughput genotyping of high-risk HPV by the di-gene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. J Clin Virol 2009;46(S3):S21-6.
17. Lee JK, Kim MK, Song SH, Hong JH, Min KJ, Kim JH, et al. Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples. Int J Gynecol Cancer 2009;19:266-72.
18. Song SH, Hong JH, Kwak SH, Lee JK, Kim MK. Clinical performance assessment of five human papillomavirus DNA tests using liquid-based cytology samples. J Obstet Gynaecol Res 2012;38:408-14.
19. Chung MY, Kim YW, Bae SM, Kwon EH, Chaturvedi PK, Battogtokh G, et al. Development of a bead-based multiplex genotyping method for diagnostic characterization of HPV infection. PLoS One 2012;7:e32259.
20. Schmitz M, Scheungraber C, Herrmann J, Teller K, Gajda M, Runnebaum IB, et al. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 2009;44:302-7.
21. Carcopino X, Henry M, Mancini J, Giussiano S, Boubli L, Olive D, et al. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 2012;84:306-13.
22. Gharizadeh B, Oggonii M, Zheng B, Akom E, Pourmand N, Ahmadian A, et al. Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. J Mol Diagn 2005;7:198-205.